Litigation Details for UCB, Inc. v. Mylan Technologies, Inc. (D. Vt. 2019)
✉ Email this page to a colleague
UCB, Inc. v. Mylan Technologies, Inc. (D. Vt. 2019)
| Docket | ⤷ Sign Up | Date Filed | 2019-08-26 |
| Court | District Court, D. Vermont | Date Terminated | 2020-07-20 |
| Cause | 35:271 Patent Infringement | Assigned To | William K. Sessions III |
| Jury Demand | None | Referred To | |
| Patents | 10,130,589; 10,350,174; 6,699,498; 6,884,434; 7,413,747; 8,246,979; 8,246,980; 8,617,591 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in UCB, Inc. v. Mylan Technologies, Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for UCB, Inc. v. Mylan Technologies, Inc. (D. Vt. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2017-04-19 | 10 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 6,699,498 B1; . (Attachments…2019 20 July 2020 2:19-cv-00148 830 Patent None District Court, D. Vermont | External link to document | |
| 2017-03-24 | 4 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,884,434 B1; 7,413,747 B2; 8,246,979…2019 20 July 2020 2:19-cv-00148 830 Patent None District Court, D. Vermont | External link to document | |
| 2017-04-19 | 8 | ’979, ’980, and ’591 patents, and U.S. Patent No. 6,699,498 (“the ’498 patent”). Mylan denies the allegations…2, 2004, the USPTO issued U.S. Patent No. 6,699,498 (“the ’498 patent”), entitled “Transdermal Therapeutic…of the ’434 Patent; the ’747 Patent; the ’979 Patent; the ’980 Patent; and the ’591 Patent. This Court…27 (“the ’747 Patent”); 8,246,979 (“the ’979 Patent”); 8,246,980 (“the ’980 Patent”); and 8,617,591… 12. The ’498 patent, as well as U.S. Patent Nos. 6,884,434 (“the ’434 patent”), 7,413,747 (“the | External link to document | |
| 2019-08-26 | 92 | Order Transferring Case | 209982), asserting U.S. Patent Nos. 10,130,589 ("the '589 Patent") and 10,350,174 ("…infringement of United States Patent Nos. 6,884,434 ("the ' 434 Patent"), 7,413 ,747 ("…quot;the ' 747 Patent"), 8,246,979 ("the ' 979 Patent"), 8,246,980 ("the …the '980 Patent"), and 8,617,591 ("the ' 591 Patent"), on May 24, 2017 (D.I. 1)…2019 (D.I. 82); WHEREAS the ' 434 Patent was the subject of a recent decision from the United | External link to document |
| 2019-08-26 | 93 | Case Transferred In - District Transfer | Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 6,699,498 B1; . (…Ï4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,884,434 … CLOSED,ANDA,PATENT U.S. District… Nature of Suit: 830 Patent … 1:19−cv−00474−LPS Cause: 35:271 Patent Infringement Plaintiff UCB, Inc. | External link to document |
| 2020-07-17 | 96 | Stipulation of Dismissal | Mylan’s counterclaims solely directed to the 6,699,498 patent are dismissed with prejudice. Mylan reserves…respect to U.S. Patent Nos. 7,413,747 (“the ’747 Patent”); 8,246,979 (“the ’979 Patent”); 8,246,980 (…(“the ’980 Patent”); and 8,617,591 (“the ’591 Patent”) (collectively the “Covenant Patents”) are hereby…to Plaintiffs’ ability to assert the Covenant Patents for any other ANDA or as provided in the Covenant…the above-captioned action with respect to U.S. Patent No. 6,884,434 are hereby dismissed without prejudice | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
